IQ-AI Limited, a company listed on the London Stock Exchange, has released its audited financial statements for the year ended December 31, 2024. The companys revenue grew by over 20% in 2024, reaching $959k (£750k), and financial results improved significantly with losses halved compared to 2023. The companys umbrella product, IB Clinic, is expanding in use and application, and it has secured GE Healthcare as a sales partner. Post-year, the company raised £250k in funds.
The companys focus areas include IB Clinic, with its various software platforms for MR DSC perfusion processing, whole-body blood flow analysis, and kidney stone and liver health assessment
IB Zero G, a technology to eliminate the need for contrast agents in imaging, which is still in early development
IB Nimblea telemedicine platform
and IB003, a Phase 1 clinical trial drug candidate for glioblastoma.
The company plans to change its name to Imaging Biometrics Limited to reflect its sole operating subsidiary. The directors share the frustration of shareholders regarding the companys market valuation and believe it has huge potential. The company has no debt and a large bank of IP, and directors believe it can achieve profitability in the near future.